Lilly reassures investors that weight-loss drug demand is strong, shares rise
Eli Lilly forecast annual profit largely above Wall Street estimates on Thursday, banking on the launch of its popular ...
Diabetes and obesity drugs fuel Eli Lilly profit in the final quarter of 2024
Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...
JD Supra10d
The GLP-1 Saga Continues: FDA Ends the Tirzepatide Shortage: Frequently Asked Questions
FDA formally announced the end of the tirzepatide shortage in a Declaratory Order issued to Eli Lilly & Co. (“Lilly”). Lilly ...
Eli Lilly Shares Fall After GLP-1 Sales Miss Expectations. Is the Stock in Trouble?
When investors are paying such high price tags for a stock, expectations are high, and any kind of miss can result in a steep ...
NBC Los Angeles1mon
FDA says the Zepbound shortage is over. Here's what that means for compounding pharmacies, patients who used off-brand versions - NBC Los Angeles
the active ingredient in Eli Lilly's weight loss drug Zepbound, is no longer in short supply. That decision will largely prevent compounding pharmacies from making and selling cheaper versions of ...
Yahoo Finance24d
Eli Lilly was hoping weight loss drug demand would be even bigger
After a review, the agency determined that Eli Lilly has enough supply to meet and exceed current and future demand of the drugs. The FDA gave compounding pharmacies 60 to 90 days, depending on ...
News1mon
FDA says knockoff versions of Lilly obesity drug must come off the market
FILE - A sign for Eli Lilly & Co. stands outside their corporate headquarters in Indianapolis on April 26, 2017. (AP Photo/Darron Cummings, File) WASHINGTON (AP) — Specialty pharmacies and ...
Wall Street Journal24d
Eli Lilly to Buy Scorpion Therapeutics Drug Program in $2.5 Billion Deal
Eli Lilly has agreed to acquire Scorpion Therapeutics’ breast cancer treatment program for up to $2.5 billion in cash. The drugmaker said Monday it is acquiring Scorpion and its STX-478 program ...
NBC 7 San Diego1mon
FDA says the Zepbound shortage is over. Here's what that means for compounding pharmacies, patients who used off-brand versions
the active ingredient in Eli Lilly's weight loss drug Zepbound, is no longer in short supply. That decision will largely prevent compounding pharmacies from making and selling cheaper versions of ...